Kornimate/medical-research-clean huggingface dataset:
impact of the blood culture technique on the diagnosis of infective endocarditis

Conditions: Bacteremia; Infective Endocarditis

Summary: to evaluate the performance of a single high volume blood culture sampling strategy versus the actually used multiple sampling strategy for the diagnosis and categorization of infective endocarditis according to the duke-li classification in a population of adults suspected of infective endocarditis.


Eligibility criteria:
inclusion criteria: * patients older than 18 years * suspected endocarditis: patients with duke-li-esc 2015 classification as a major morphological criterion or at least two minor criteria, other than a microbiological criterion, will be considered suspicious of infectious endocarditis. * not objecting to their inclusion in the study after delivery and explanation of the information form. * absence of microbiological documentation sought or available at the time of inclusion (a patient having already had negative blood cultures or being identified during the screening can be included). exclusion criteria: * antibiotherapy adapted to a situation of endocarditis, introduced more than 24 hours or stopped for less than 7 days in case of therapeutic window. * any previous antibiotic therapy in the 7 days preceding the inclusion leading to an improvement in the clinical symptomatology. * state of consciousness not allowing loyal information.

Keywords: diagnosis blood culture
rak-pride: optimizing proton pump inhibitor use through education and intervention

Conditions: Proton Pump Inhibitors; Deprescribing; Inappropriate Use

Summary: the goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (ppis) among adult patients (≥18 years) with potentially inappropriate ppi prescriptions in ras al khaimah. the main questions it aims to answer are: * can a pharmacist-led education program reduce unnecessary ppi use? * does the intervention improve patients' quality of life and reduce healthcare costs? researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces ppi use and improves patient outcomes. participants will: * receive educational materials from pharmacists, including a patient educational brochure, ppi patient decision aid, ppi deprescribing pamphlet, and ppi patient action plan. * physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, ppi evidence-based deprescribing guideline, ppi deprescribing algorithm, and whiteboard videos on ppi deprescribing. * patients will be followed up for 6 months to monitor changes in ppi use, symptoms, and quality of life.

the rak-pride study aims to evaluate the impact of a pharmacist-led educational intervention on the inappropriate use of proton pump inhibitors (ppis) among adult patients in ras al khaimah. this intervention will focus on both patient education and physician guidance, promoting evidence-based deprescribing practices for ppis.

Eligibility criteria:
inclusion criteria: physicians will be eligible to participate if: * they are prescribing ppis in outpatient department of the study sites * they have patients with potentially inappropriate ppi prescriptions patients will be eligible to participate if: * they are ≥18 years * they are presenting to out-patient departments of the study sites * they have prescriptions of potentially inappropriate ppis * their treating physicians are included in the study exclusion criteria: physicians will be excluded if: • they are involved in any other prescribing trial patients will be excluded if: * they are unable to give informed consent, as judged by their physicians * they have definitive indications for ppi use

Keywords: proton pump inhibitors peptic ulcer disease deprescribing pharmacist-led educational intervention inappropriate use rak - pride
hkt-500 in adult patients with ankle sprain

Conditions: Ankle Sprain

Summary: the objective of this study is to demonstrate the multiple-dose efficacy and safety of hkt-500 for the treatment of ankle sprain.

randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.

Eligibility criteria:
inclusion criteria: * grade i or grade ii ankle sprain. exclusion criteria: * the subject is a women of childbearing potential who has a positive urine pregnancy test, who is lactating, who is not surgically sterile (by tubal ligation or hysterectomy), or at least 2 years postmenopausal, and has not practice an acceptable form of birth control (defined as the use of an intrauterine device with spermicide, a barrier method with spermicide, condoms with spermicide, subdermal implant, oral contraceptives, or abstinence) for at least 2 months prior to visit 1.

Keywords: sprain ankle pain
covid-19 in patients with chronic liver diseases

Conditions: COVID-19; Chronic Liver Disease

Summary: this study seeks to determine how covid-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of covid-19 is influenced by underlying chronic liver disease.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of covid-19 * personal history of either * chronic hepatitis c * chronic hepatitis b * alcoholic liver disease * non alcoholic liver disease * autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis * cryptogenic cirrhosis * hepatocellular carcinoma exclusion criteria: * non-covid-19 patient
crizanlizumab for treating covid-19 vasculopathy

Conditions: COVID-19

Summary: the purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with covid-19.

infection with severe acute respiratory syndrome (sars) coronavirus 2 (cov-2) causes coronavirus disease 2019 (covid-19). the clinical course of covid-19 is variable, and some patients develop severe pneumonia, multi-organ failure, and shock. severe covid-19 is characterized by a hyper-inflammatory and hyper-thrombotic state. we propose that this state is caused by viral injury of the vascular endothelium, leading to endothelial release of von willebrand factor (vwf) and p-selectin, which in turn drive thrombosis and vascular inflammation. crizanlizumab is a monoclonal antibody that targets p-selectin. crizanlizumab can decrease inflammation by binding to p-selectin, blocking leucocyte and platelet adherence to the vessel wall. we now plan to test the safety and efficacy of crizanlizumab in decreasing biomarkers of inflammation and thrombosis in a placebo-controlled, double-blind randomized clinical trial

Eligibility criteria:
inclusion criteria: 1. willing to provide written informed consent 2. willing to comply with all study procedures and be available for the duration of the study 3. male or female ≥ 18 years of age 4. sars-cov-2 infection (covid-19) within the past 10 d documented by laboratory test (nucleic acid test (nat) or reverse transcriptase-polymerase chain reaction (rt-pcr)) 5. currently hospitalized 6. symptoms of acute respiratory infection (at least one of the following: cough, fever \> 37.5°c, dyspnea, sore throat, anosmia), 7. radiographic evidence of pulmonary infiltrates 8. requiring supplemental oxygen or the peripheral capillary oxygenation saturation (spo2) \< 94% on room air at screening 9. elevated d-dimer \> 0.49 mg/l 10. negative pregnancy test for females of childbearing potential exclusion criteria: 1. use of home oxygen at baseline 2. current use of mechanical ventilation 3. inability to provide consent 4. do not intubate status 5. prisoner or incarcerated 6. pregnancy or breast feeding 7. participation in other interventional therapy trials for covid-19. 8. international normalized ratio (inr) \> 3 or activated partial thromboplastin time (aptt) \> 60

Keywords: coronavirus
evaluation of the physiodoloris pain monitor in patients with complex regional pain syndrome

Conditions: Complex Regional Pain Syndrome

Summary: a french university team (m. jeanne, md, and m. logier, ph d) have developed a pain assessment tool based on the analysis of the variability heart rate which evaluates the analgesia nociception index (ani). this index is intended to give a quantification of pain. the aim of the present study is to assess the validity of the ani parameter in patients with complex regional pain syndrome treated with a nerve block (reversible pain).


Eligibility criteria:
inclusion criteria: * patients suffering from a complex regional pain syndrome of the upper or lower limb exclusion criteria: * contra-indication of a nerve block, * contra-indication of the use of the pain monitor
in patients with carpal tunnel syndrome, median nerve conduction is evaluated after nerve mobilizations

Conditions: Carpal Tunnel Syndrome

Summary: this project is linked to the line of research on carpal tunnel syndrome, of the physiuzerapy research group, belonging to the university of zaragoza. within this line, the biomechanical and physiological effect of the proposed technique has been investigated, both in healthy subjects, in cadavers and in patients with carpal tunnel syndrome (cts), resulting in the reading of 2 doctoral theses, the publication of 9 articles in high-impact journals. and the patent for a splint for the treatment of pathology. this project aims to provide information that is still lacking on the immediate effect of these techniques in patients with cts. for this, there will be three groups of patients from the lozano blesa university clinical hospital distributed randomly. in two of the groups, sliding and neural tension techniques will be carried out (case group). the remaining group (control group) will be taken as a reference by performing a placebo treatment. before and after carrying out these techniques, electrophysiological data will be collected to be able to compare them. this comparison is based on highlighting the differences between the data before the techniques and after, as well as between the case group and the control group.


Eligibility criteria:
inclusion criteria: * being over 18 years * present carpal tunnel syndrome diagnosed by electroneurogram * have understanding and communication skills * give consent to participate in the study exclusion criteria: * have received previous surgery on the hand or wrist * present a severe limitation of movement in any of the joints of the affected upper limb * not signing the informed consent
predictors affecting long-term use of solifenacin or mirabegron in women with overactive bladder syndrome

Conditions: Overactive Bladder Syndrome

Summary: a retrospective analysis of medical records at far eastern memorial hospital from january 2008 to may 2020 about female patients with overactive bladder syndrome, who received solifenacin or mirabegron as the initial treatment. factors affecting persistence of oab medications will be analyzed.


Eligibility criteria:
inclusion criteria: * women with overactive bladder syndrome received solifenacin or mirabegron as the initial treatment exclusion criteria: * \<20 year-old
a research study looking at how well a combination of the medicines semaglutide and nnc0480-0389 works in people with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study is looking at semaglutide in combination with a potential new medicine (nnc0480-0389) in people with type 2 diabetes. the study is being conducted to see how well semaglutide, in combination with different doses of nnc0480-0389, work to lower blood sugar levels. results from this study will be used to select the doses of the two medicines for other studies. participants will either get: semaglutide (a medicine doctors can already prescribe for treatment of type 2 diabetes) in combination with nnc0480-0389 (a potential new medicine) or placebo (a 'dummy' medicine that looks like the medicines but without any medicine). nnc0480-0389 alone, or semaglutide alone which treatment participant get is decided by chance. participant will need to take 2-3 injections once every week during the study. one injection will be with semaglutide or placebo and 1-2 injections will be with nnc0480-0389 or placebo. participant must inject the study medicines themself into the stomach, thigh, or upper arm. the study will last for about 41weeks. participant will have 20 clinic visits. participant will have blood samples taken at all clinic visits. at 3 clinic visits, participant will also have an electrocardiogram (ecg). this is a test to check participants heart. participant will have their eyes checked before or at the start of the study and at the end of the study. women can only take part in the study if they are not able to become pregnant


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening * participants treated with diet and exercise as monotherapy or in combination with stable daily dose(s) greater than or equal to 90 days before screening of any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose * hba1c 7.0-10.0% (53-86 mmol/mol) (both inclusive) * bmi greater than or equal to 25 and below 40 kg/m\^2 exclusion criteria: * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. however, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination * presence or history of any clinically relevant respiratory, metabolic, renal, hepatic cardiovascular, gastrointestinal, or endocrinological conditions (except conditions associated with t2d)
corticostriatal contributions to parkinson's disease cognitive impairment

Conditions: Parkinson Disease

Summary: the goal of this study is to learn more about the brain activity underlying parkinson's disease cognitive impairment. the investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity underlying nonmotor symptoms of parkinson's disease.


Eligibility criteria:
inclusion criteria: * scheduled to undergo deep brain stimulation surgery under local anesthesia at vanderbilt university medical center * planned clinical electrode trajectory that contacts caudate * age greater than or equal to 40 * diagnosis of parkinson's disease * able to participate in intraoperative testing * english speaking exclusion criteria: * age less than 40 * not able to participate in intraoperative testing (for example unable to comprehend instructions or follow directions) * movement disorder other than parkinson's disease

Keywords: deep brain stimulation
infranodal conduction time during tavr as predictor of havb

Conditions: Severe Aortic Valve Stenosis; High-degree AV Block; Left Bundle-Branch Block

Summary: consecutive patients with high grade aortic stenosis undergoing transcatheter aortic valve replacement (tavr) with a self-expanding valve (medtronic corevalve evolut r® or edwards sapien s3®) without pre-existing pacemaker devices are eligible for inclusion. during the tavr procedure, an electrophysiologic study including measurements of infranodal conduction times (hv-interval before and after valve implantation) will be performed. electrocardiograms before tavr, before discharge, after 30 days and after 12 months will be analyzed regarding new onset lbb and the occurrence of high-degree av block (havb) .


Eligibility criteria:
inclusion criteria: 1. indication for tavr according to current guidelines 2. written informed consent exclusion criteria: 1. pre-existent intracardiac device as pacemaker, implanted cardioverter defibrillator or crt-p/crt-d device

Keywords: transcatheter valve replacement infranodal conduction time high-degree av block left bundle-branch block
contact to a physician specialized in social medicine and return to work

Conditions: Return to Work; Musculoskeletal Disease

Summary: the aim of this study was to investigate the impact of a rehabilitation program including a physician specialized in social medicine parallel to treatment for suspected spinal disc herniation.

in a two-year time period (2011 to 2012) 443 patients of suspected of disc herniation and risk of low work ability - based on questionnaires participated in a randomized control trial. the patients were randomized to either the intervention group (n=220) or control group (n=223). the intervention group were invited to the department of social medicine two to four weeks after their first contact to department of rheumatology for a consultation with a physician specialized in social medicine. together with the patient a return-to-work (rtw) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. throughout the intervention, the patients received their usual treatment from the department of rheumatology like patients from the control group. outcome was return to the work force at one year follow up using information from a national registry.

Eligibility criteria:
inclusion criteria: * age ≥ 18 and \< 60 years old, * not receiving disability pension and not on maternity leave. * sick leave over the past year for more than ten days * low self-rated work ability for the next two years * health anxiety exclusion criteria: -
the pharmacokinetics of ketamine in the breast milk of lactating women

Conditions: Ketamine; Lactation

Summary: quantification of ketamine in breast milk at 3 hour intervals up to 30 hours-- obtained from lactating women who receive 2 different intramuscular injections of ketamine on two separate days at least 5 days apart.

quantification of ketamine in breast milk at 3 hour intervals up to 30 hours-- obtained from lactating women who receive 2 different intramuscular injections of ketamine on two separate days at least 5 days apart: 0.5mg/kg and 1.0mg kg. women are required to have been breast feeding for at least 3 months and be healthy and on no medications. support is provided for the entire time at the site and for any at home pumping. during the period of ketamine's influence, subjects are reclining and with 2 investigators. the initial subject's data will determine the length of time for pumping--most likely 12 hours as ketamine and the active principle metabolite have half-lives of less than 3 hours. determination of concentration of ketamine in breast milk is being done at the ucsf clinical lab with quantification of metabolites that are inactive as well. this research is of benefit by providing lactating women information on potential exposure of infants/children to ketamine. it will serve as a guide as krf conducts research on postpartum depression and for women at large using ketamine for psychiatric indications.

Eligibility criteria:
inclusion criteria:• age 21-45 * postpartum with established lactation for a minimum of 3 months. * ability to pump breast milk and to provide a reservoir for infant feeding prior to the study; or acceptance of bottle feeding by the infant. * in good health-normal bp/p; afebrile-temp ascertained; review of systems by md; absence of diagnosed illnesses. * not pregnant--pregnancy tested for before each administration by urine assay. exclusion criteria:• hypertension with a bp greater than 145/90 * subjects must be off all psychiatric medications specifically; medications and supplements, or evaluated by the pi for non-interference * no alcohol or other substances such as marijuana for 72 hours or more. * weight \ 90kg. * pregnancy

Keywords: ketamine lactation postpartum depression breastfeeding infant exposure
impact of pacing site and av delay on blood pressure in hypertensive patients

Conditions: Hypertension

Summary: the purpose of this study is to test whether the a-v sequential pacing strategy shown to effectively reduce blood pressure in a dog model of hypertension also reduces blood pressure acutely in patients with hypertension (systolic blood pressure greater than 140 mmhg) despite medical treatments.


Eligibility criteria:
inclusion criteria: 1. patient has hypertension with systolic blood pressure \>140 mmhg despite at least one antihypertensive medication. 2. patient has a clinical indication for a pacemaker or an electrophysiology study involving introduction of transvenous electrophysiology catheters to the right atrium and/or right ventricle. 3. patient is willing and able to provide informed consent exclusion criteria: 1. patient is in atrial fibrillation at the time of the study 2. patient has an ejection fraction less than 45% 3. patient has a history of symptomatic heart failure, regardless of ef 4. patient is undergoing an ablation procedure for a bypass track (wpw) 5. patient has a history of resuscitation from ventricular fibrillation or sustained ventricular tachycardia

Keywords: hypertension resistant to conventional therapy
corimuno-ana: trial evaluating efficacy of anakinra in patients with covid-19 infection

Conditions: Corona Virus Infection

Summary: the overall objective of the study is to determine the therapeutic effect and tolerance of anakinra in patients with moderate, severe pneumonia or critical pneumonia associated with coronavirus disease 2019 (covid-19). anakinra (ana) is a recombinant human decoy il-1ra and therefore blocks il-1α and il-1β. the study has a cohort multiple randomized controlled trials (cmrct) design. randomization will occur prior to offering anakinra administration to patients enrolled in the corimuno-19 cohort. anakinra will be administered to consenting adult patients hospitalized with corvid-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. patients who will chose not to receive anakinra will receive standard of cares. outcomes of anakinra -treated patients will be compared with outcomes of standard of care treated patients as well as outcomes of patients treated with other immune modulators.


Eligibility criteria:
inclusion criteria: 1. patients included in the corimuno-19 cohort 2. patients with c-reactive protein level (crp) \> 25 mg / l the day or the day before the infusion) 3. patients belonging to one of the 2 following groups: * group 1: patients meeting all of the following criteria: 1) requiring more than 3l/min of oxygen; 2) who progression scale = 5; 3) no non invasive ventilation or high flow * group 2: patients with respiratory failure and (requiring mechanical ventilation or non invasive ventilation or high flow), with a who progression scale ≥ 6, and no do-not-resuscitate (dnr) order exclusion criteria: * patients with exclusion criteria to the corimuno-19 cohort. * known hypersensitivity to anakinra or to any of their excipients. * pregnancy * current documented bacterial infection. * patient with any of following laboratory results out of the ranges detailed below at screening: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n * severe renal insufficiency with glomerular filtration rate \< 30 ml / mn